Tagrix (Osimertinib) is the first of its kind to be indicated for patients with T790M mutation-positive NSCLC, irrespective of previous treatment with an EGFR tyrosine kinase inhibitor (TKI).

Mutations in the EGFR receptor can lead to uncontrolled cell growth and tumour formation.

Tagrix (Osimertinib) targets both the EGFR mutation that triggers cancer development and T790M, a mutation that makes tumours resistant to existing treatment with EGFR-TKIs.